Sep 16, 2020 / 08:40PM GMT
Alethia Rene Young - Cantor Fitzgerald & Co., Research Division - Head of Healthcare Research
Hey, everybody. It's Alethia Young. I cover  large-cap, small, mid-cap biotech here at Cantor. Very happy to have Exelixis here with me to round out day 2, saving the best for last.
We have Dr. Mike Morrissey, who is Director, President and CEO of Exelixis. And we'll be doing a fireside chat for 30 minutes and a lot to work through. But Mike can (inaudible) going first, which is 9ER. Surprise, surprise.
Questions and Answers:
Alethia Rene Young - Cantor Fitzgerald & Co., Research Division - Head of Healthcare ResearchBut it's obviously a huge focus. And just -- I want you to just frame what you can for us around some of the new analysis that we'll get and how to think about some of those results relative to the competition?
Michael M. Morrissey - Exelixis, Inc. - CEO, President & Director
Yes. For sure. Well, thanks again for having us. We've had a great day meeting with investors at your